Reena Pharma India Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.95 M
as on 24-10-2024
- Company Age 23 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.80 M
as on 24-10-2024
- Satisfied Charges ₹ 6.91 Cr
as on 24-10-2024
- Revenue 78.73%
(FY 2023)
- Profit 109.16%
(FY 2023)
- Ebitda 202.04%
(FY 2023)
- Net Worth 3.85%
(FY 2023)
- Total Assets 2.16%
(FY 2023)
About Reena Pharma India
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.95 M.
The company currently has active open charges totaling ₹8.80 M. The company has closed loans amounting to ₹6.91 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shivagouda Patil, Savita Patil, Shashidhar Patil, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231MH2001PTC132736
- Company No.
132736
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jul 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNavi Mumbai, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Reena Pharma India?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivagouda Patil  | Director | 16-Jul-2001 | Current |
| Savita Patil | Director | 16-Jul-2001 | Current |
| Shashidhar Patil | Director | 01-Jul-2013 | Current |
| Haresh Mehta | Director | 01-Nov-2012 | Current |
| Ila Mehta | Director | 01-Nov-2012 | Current |
Financial Performance of Reena Pharma India.
Reena Pharma India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 78.73% increase. The company also saw a substantial improvement in profitability, with a 109.16% increase in profit. The company's net worth moved up by a moderate rise of 3.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Reena Pharma India?
In 2023, Reena Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Mar 2024 | ₹5.10 M | Open |
New India Co-Op Bank Limited Creation Date: 11 Aug 2021 | ₹1.70 M | Open |
New India Co-Op Bank Limited Creation Date: 27 Jun 2018 | ₹2.00 M | Open |
How Many Employees Work at Reena Pharma India?
Reena Pharma India has a workforce of 7 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reena Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reena Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
